His lab is focusing on refining the alanine-scanning assay to a few vital residues that could accurately distinguish between fibrils from neurodegenerative tauopathies. He envisions applying this streamlined assay for postmortem neuropathological prognosis, and possibly for blood screening of tauopathies.From the La Biennale di Venezia Web-site: �